Earnings Call · Q4 FY2022·2023-03-09

Q4 22EPS +78.95%·Rev n/aQ3 22EPS -100.00%*·Rev n/aQ2 22EPS +100.00%*·Rev n/aQ1 22EPS -20.69%·Rev n/a⚠ consensus missing

Akebia Therapeutics, Inc. AKBA

Mercedes Carrasco — Investor Relations or Communications Officer

John Butler — Chief Executive Officer (CEO)

UTHealth — Executive (likely senior management involved in R&D or commercial operations)

PHI — Executive (likely Chief Commercial Officer or similar) based on context of discussing product labels and FDA interactions

David Spellman — Chief Financial Officer (CFO)

−22.3%1d on move date−20.4% vs SPY3d−26.7%5d−34.8%

Research tier

Behavioral profile computed for 5 speakers on this call.

Sign in to view the Behavioral Lean, the Behavioral Deviation Score, the speaker decomposition, and the novel forward-guidance phrases flagged on this call — each scored against the speaker's own prior-call baseline.

Behavioral data on every earnings call

Per-speaker language deviation, scored against each executive's own history. Explore more AKBA calls or request research access.

More AKBA calls Browse calls Request research access